Clene Inc (CLNN) FinancialsCLNNClene Inc

Clene Inc (CLNN) generates its revenue primarily from Supplements, which accounts for 100.0% of total sales, equivalent to $108.00K. Understanding this concentration is critical for investors evaluating how CLNN navigates market cycles within the Biotechnology & Medical Research industry.

Evaluating the bottom line, Clene Inc maintains a gross margin of 71.43%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at -11333.93%, while the net margin is 6991.07%. These profitability ratios, combined with a Return on Equity (ROE) of 197.50%, provide a clear picture of how effectively CLNN converts its operational activities into shareholder value.

In the context of the broader market, CLNN competes directly with industry leaders such as TLPH and XLO. With a market capitalization of $57.17M, it holds a leading position in the sector. When comparing efficiency, CLNN's gross margin of 71.43% stands against TLPH's N/A and XLO's 100.00%. Such benchmarking helps identify whether Clene Inc is trading at a premium or discount relative to its financial performance.

Clene's financial performance shows a troubling trend with a net income loss of $13.42 million in Q2 2026 and a gross margin of 60% in the same quarter, indicating challenges in revenue generation despite high gross margins.